Structure-Guided Design of Selective Epac1 and Epac2 Agonists

PLoS Biology

Volumn 13, Issue 1, 2015, Pages

  Schwede, Frank ^a   Bertinetti, Daniela ^b   Langerijs, Carianne N ^c   Hadders, Michael A ^d   Wienk, Hans ^d   Ellenbroek, Johanne H ^e   de Koning, Eelco J P ^e,f   Bos, Johannes L ^f   Herberg, Friedrich W ^b   Genieser, Hans Gottfried ^a   Janssen, Richard A J ^c   Rehmann, Holger ^f  

^a BIOLOG Life Science Institute   (Germany)

^b UNIVERSITY OF KASSEL   (Germany)

^c Galapagos BV   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

8 (4 CHLOROPHENYLTHIO) CYCLIC AMP; 8 BROMO CYCLIC AMP; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR EPAC1; GUANINE NUCLEOTIDE EXCHANGE FACTOR EPAC2; UNCLASSIFIED DRUG; INSULIN; PROTEIN BINDING; RAPGEF3 PROTEIN, HUMAN; RAPGEF4 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; CELL STRAIN; CHEMICAL MODIFICATION; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; INSULIN RELEASE; LIGAND BINDING; PANCREAS ISLET BETA CELL; STRUCTURE ACTIVITY RELATION; AGONISTS; ANALOGS AND DERIVATIVES; BINDING SITE; CHEMISTRY; DRUG EFFECTS; HUMAN; MOLECULAR MODEL; PANCREAS ISLET; PHYSIOLOGY; SECRETION (PROCESS); TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; CYCLIC AMP; DRUG DESIGN; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; INSULIN; ISLETS OF LANGERHANS; MODELS, MOLECULAR; PROTEIN BINDING;

EID: 84922235719     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1002038     Document Type: Article

References (66)

1. Cook DL, Hales CN, (1984) Intracellular ATP directly blocks K+ channels in pancreatic B-cells. Nature 311: 271–273. 6090930
2. Inagaki N, Gonoi T, Clement JP, Namba N, Inazawa J, et al. (1995) Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 270: 1166–1170. 7502040
3. Speier S, Yang SB, Sroka K, Rose T, Rupnik M, (2005) KATP-channels in beta-cells in tissue slices are directly modulated by millimolar ATP. Mol Cell Endocrinol 230: 51–58. 15664451
4. Doyle ME, Egan JM, (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113: 546–593. doi: 10.1016/j.pharmthera.2006.11.007 17306374
5. Baggio LL, Drucker DJ, (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131–2157. 17498508
6. Beavo JA, Brunton LL, (2002) Cyclic nucleotide research—still expanding after half a century. Nat Rev Mol Cell Biol 3: 710–718. 12209131
7. Rehmann H, Wittinghofer A, Bos JL, (2007) Capturing cyclic nucleotides in action: snapshots from crystallographic studies. Nat Rev Mol Cell Biol 8: 63–73. 17183361
8. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, et al. (1998) A family of cAMP-binding proteins that directly activate Rap1. Science 282: 2275–2279. 9856955
9. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, et al. (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396: 474–477. 9853756
10. Rehmann H, Arias-Palomo E, Hadders MA, Schwede F, Llorca O, et al. (2008) Structure of Epac2 in complex with a cyclic AMP analogue and RAP1B. Nature 455: 124–127. doi: 10.1038/nature07187 18660803
11. Rehmann H, Das J, Knipscheer P, Wittinghofer A, Bos JL, (2006) Structure of the cyclic-AMP-responsive exchange factor Epac2 in its auto-inhibited state. Nature 439: 625–628. 16452984
12. Rehmann H, (2006) Characterization of the activation of the Rap-specific exchange factor Epac by cyclic nucleotides. Methods Enzymol 407: 159–173. 16757322
13. Rehmann H, Schwede F, Doskeland SO, Wittinghofer A, Bos JL, (2003) Ligand-mediated activation of the cAMP-responsive guanine nucleotide exchange factor Epac. J Biol Chem 278: 38548–38556. 12888551
14. Harris TE, Persaud SJ, Jones PM, (1997) Pseudosubstrate inhibition of cyclic AMP-dependent protein kinase in intact pancreatic islets: effects on cyclic AMP-dependent and glucose-dependent insulin secretion. Biochem Biophys Res Commun 232: 648–651. 9126329
15. Renstrom E, Eliasson L, Rorsman P, (1997) Protein kinase A-dependent and -independent stimulation of exocytosis by cAMP in mouse pancreatic B-cells. J Physiol 502: 105–118. 9234200
16. Chepurny OG, Kelley GG, Dzhura I, Leech CA, Roe MW, et al. (2010) PKA-dependent potentiation of glucose-stimulated insulin secretion by Epac activator 8-pCPT-2′-O-Me-cAMP-AM in human islets of Langerhans. Am J Physiol Endocrinol Metab 298: E622–633. doi: 10.1152/ajpendo.00630.2009 20009023
17. Sedej S, Rose T, Rupnik M, (2005) cAMP increases Ca2+-dependent exocytosis through both PKA and Epac2 in mouse melanotrophs from pituitary tissue slices. J Physiol 567: 799–813. doi: 10.1113/jphysiol.2005.090381 15994184
18. Nakazaki M, Crane A, Hu M, Seghers V, Ullrich S, et al. (2002) cAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets. Diabetes 51: 3440–3449. 12453898
19. Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, et al. (2001) Critical role of cAMP-GEFII—Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 276: 46046–46053. 11598134
20. Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, et al. (2000) cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2: 805–811. 11056535
21. Kang G, Chepurny OG, Holz GG, (2001) cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells. J Physiol 536: 375–385. doi: 10.1111/j.1469-7793.2001.0375c.xd 11600673
22. Kang G, Joseph JW, Chepurny OG, Monaco M, Wheeler MB, et al. (2003) Epac-selective cAMP analog 8-pCPT-2′-O-Me-cAMP as a stimulus for Ca2+- induced Ca2+ release and exocytosis in pancreatic beta-cells. J Biol Chem 278: 8279–8285. doi: 10.1074/jbc.M211682200 12496249
23. Idevall-Hagren O, Barg S, Gylfe E, Tengholm A, (2010) cAMP mediators of pulsatile insulin secretion from glucose-stimulated single beta-cells. J Biol Chem 285: 23007–23018. doi: 10.1074/jbc.M109.095992 20498366
24. Shibasaki T, Takahashi H, Miki T, Sunaga Y, Matsumura K, et al. (2007) Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A 104: 19333–19338. doi: 10.1073/pnas.0707054104 18040047
25. Eliasson L, Ma X, Renstrom E, Barg S, Berggren PO, et al. (2003) SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells. J Gen Physiol 121: 181–197. doi: 10.1085/jgp.20028707 12601083
26. Leech CA, Holz GG, Chepurny O, Habener JF, (2000) Expression of cAMP-regulated guanine nucleotide exchange factors in pancreatic beta-cells. BiochemBiophysResCommun 278: 44–47. doi: 10.1006/bbrc.2000.3763 11071853
27. Skelin M, Rupnik M, (2011) cAMP increases the sensitivity of exocytosis to Ca(2)+ primarily through protein kinase A in mouse pancreatic beta cells. Cell Calcium 49: 89–99. doi: 10.1016/j.ceca.2010.12.005 21242000
28. Zhang CL, Katoh M, Shibasaki T, Minami K, Sunaga Y, et al. (2009) The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 325: 607–610. doi: 10.1126/science.1172256 19644119
29. Tsalkova T, Gribenko AV, Cheng X, (2011) Exchange protein directly activated by cyclic AMP isoform 2 is not a direct target of sulfonylurea drugs. Assay Drug DevTechnol 9: 88–91. doi: 10.1089/adt.2010.0338 21133673
30. Rehmann H, (2012) Epac2: a sulfonylurea receptor? Biochem Soc T 40: 6–10. doi: 10.1042/BST20110640 22260657
31. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, et al. (2013) GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 19: 567–575. doi: 10.1038/nm.3128 23542788
32. Labuzek K, Kozlowski M, Szkudlapski D, Sikorska P, Kozlowska M, et al. (2013) Incretin-based therapies in the treatment of type 2 diabetes—more than meets the eye? Eur J Intern Med 24: 207–212. doi: 10.1016/j.ejim.2013.01.009 23375875
33. Alves C, Batel-Marques F, Macedo AF, (2012) A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 98: 271–284. doi: 10.1016/j.diabres.2012.09.008 23010561
34. Enserink JM, Christensen AE, de Rooij J, van Triest M, Schwede F, et al. (2002) A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat Cell Biol 4: 901–906. 12402047
35. Christensen AE, Selheim F, de Rooij J, Dremier S, Schwede F, et al. (2003) cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J Biol Chem 278: 35394–35402. 12819211
36. Su Y, Dostmann WR, Herberg FW, Durick K, Xuong NH, et al. (1995) Regulatory subunit of protein kinase A: structure of deletion mutant with cAMP binding domains. Science 269: 807–813. 7638597
37. Zagotta WN, Olivier NB, Black KD, Young EC, Olson R, et al. (2003) Structural basis for modulation and agonist specificity of HCN pacemaker channels. Nature 425: 200–205. 12968185
38. Moll D, Prinz A, Gesellchen F, Drewianka S, Zimmermann B, et al. (2006) Biomolecular interaction analysis in functional proteomics. J Neural Transm 113: 1015–1032. 16835689
39. Moll D, Prinz A, Brendel CM, Berrera M, Guske K, et al. (2008) Biochemical characterization and cellular imaging of a novel, membrane permeable fluorescent cAMP analog. BMC Biochem 9: 18. doi: 10.1186/1471-2091-9-18 18578870
40. Dostmann WR, Taylor SS, Genieser HG, Jastorff B, Døskeland SO, et al. (1990) Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3′,5′-cyclic phosphorothioates. J Biol Chem 265: 10484–10491. 2162349
41. De Wit RJ, Hoppe J, Stec WJ, Baraniak J, Jastorff B, (1982) Interaction of cAMP derivatives with the ‘stable’ cAMP-binding site in the cAMP-dependent protein kinase type I. Eur J Biochem 122: 95–99. 6277633
42. Yagura TS, Miller JP, (1981) Mapping adenosine cyclic 3′,5′-phosphate binding sites on type I and type II adenosine cyclic 3′,5′-phosphate dependent protein kinases using ribose ring and cyclic phosphate ring analogues of adenosine cyclic 3′,5′-phosphate. Biochemistry 20: 879–887. 6260142
43. Dodge-Kafka KL, Soughayer J, Pare GC, Carlisle Michel JJ, Langeberg LK, et al. (2005) The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 437: 574–578. doi: 10.1038/nature03966 16177794
44. Woolfrey KM, Srivastava DP, Photowala H, Yamashita M, Barbolina MV, et al. (2009) Epac2 induces synapse remodeling and depression and its disease-associated forms alter spines. Nat Neurosci 12: 1275–1284. doi: 10.1038/nn.2386 19734897
45. Chepurny OG, Leech CA, Kelley GG, Dzhura I, Dzhura E, et al. (2009) Enhanced Rap1 activation and insulin secretagogue properties of an acetoxymethyl ester of an Epac-selective cyclic AMP analog in rat INS-1 cells: studies with 8-pCPT-2′-O-Me-cAMP-AM. J Biol Chem 284: 10728–10736. doi: 10.1074/jbc.M900166200 19244230
46. Vliem MJ, Ponsioen B, Schwede F, Pannekoek WJ, Riedl J, et al. (2008) 8-pCPT-2′-O-Me-cAMP-AM: an improved Epac-selective cAMP analogue. Chembiochem 9: 2052–2054. doi: 10.1002/cbic.200800216 18633951
47. Chen H, Wild C, Zhou X, Ye N, Cheng X, et al. (2014) Recent advances in the discovery of small molecules targeting exchange proteins directly activated by cAMP (EPAC). J Med Chem 57: 3651–3665. doi: 10.1021/jm401425e 24256330
48. Hidaka H, Watanabe M, Kobayashi R, (1991) Properties and use of H-series compounds as protein kinase inhibitors. Methods Enzymol 201: 328–339. 1658551
49. Lochner A, Moolman JA, (2006) The many faces of H89: a review. Cardiovasc Drug Rev 24: 261–274. 17214602
50. Walsh DA, Ashby CD, Gonzalez C, Calkins D, Fischer EH, et al. (1971) Purification and characterization of a protein inhibitor of adenosine 3′,5′-monophosphate-dependent protein kinases. J Biol Chem 246: 1977–1985. 4324557
51. Walsh DA, Glass DB, (1991) Utilization of the inhibitor protein of adenosine cyclic monophosphate- dependent protein kinase, and peptides derived from it, as tools to study adenosine cyclic monophosphate-mediated cellular processes. Methods Enzymol 201: 304–316. 1658550
52. Tsalkova T, Mei FC, Li S, Chepurny OG, Leech CA, et al. (2012) Isoform-specific antagonists of exchange proteins directly activated by cAMP. Proc Natl Acad Sci U S A 109: 18613–18618. doi: 10.1073/pnas.1210209109 23091014
53. Rehmann H, (2013) Epac-inhibitors: facts and artefacts. Sci Rep 3: 3032. doi: 10.1038/srep03032 24149987
54. Chen H, Tsalkova T, Chepurny OG, Mei FC, Holz GG, et al. (2013) Identification and characterization of small molecules as potent and specific EPAC2 antagonists. J Med Chem 56: 952–962. doi: 10.1021/jm3014162 23286832
55. Courilleau D, Bisserier M, Jullian JC, Lucas A, Bouyssou P, et al. (2012) Identification of a tetrahydroquinoline analog as a pharmacological inhibitor of the cAMP-binding protein Epac. J Biol Chem 287: 44192–44202. doi: 10.1074/jbc.M112.422956 23139415
56. Courilleau D, Bouyssou P, Fischmeister R, Lezoualc’h F, Blondeau JP, (2013) The (R)-enantiomer of CE3F4 is a preferential inhibitor of human exchange protein directly activated by cyclic AMP isoform 1 (Epac1). Biochem Biophys Res Commun 440: 443–448. doi: 10.1016/j.bbrc.2013.09.107 24099776
57. Rehmann H, Prakash B, Wolf E, Rueppel A, de RJ, et al. (2003) Structure and regulation of the cAMP-binding domains of Epac2. Nat Struct Biol 10: 26–32. 12469113
58. Chepurny OG, Bertinetti D, Diskar M, Leech CA, Afshari P, et al. (2013) Stimulation of proglucagon gene expression by human GPR119 in enteroendocrine L-cell line GLUTag. Mol Endocrinol 27: 1267–1282. doi: 10.1210/me.2013-1029 23798572
59. Cook PF, Neville ME, Jr.Vrana KE, Hartl FT, Roskoski R, Jr. (1982) Adenosine cyclic 3′,5′-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit. Biochemistry 21: 5794–5799. 6295440
60. Spijker HS, Ravelli RB, Mommaas-Kienhuis AM, van Apeldoorn AA, Engelse MA, et al. (2013) Conversion of mature human beta-cells into glucagon-producing alpha-cells. Diabetes 62: 2471–2480. doi: 10.2337/db12-1001 23569174
61. Kataoka S, Imai J, Yamaji N, Kato M, Kawada T, et al. (1990) Studies on the synthesis of compounds related to adenosine-3′,5′-cyclic phosphate. VI. Synthesis and cardiac effects of N6,N6,2′-O-trialkyl-, N6,2′-O-dialkyl-, and 2′-O-alkyladenosine-3′,5′-cyclic phosphates. Chem Pharm Bull (Tokyo) 38: 1596–1600. 2170037
62. Genieser HG, Butt E, Bottin U, Dostmann W, Jastorff B (1989) Synthesis of the 3′,5′-cyclic phosphates from unprotected nucleosides. Synthesis-Stuttgart: 53–54.
63. Genieser HG, Dostmann W, Bottin U, Butt E, Jastorff B, (1988) Synthesis of nucleoside-3′,5′-cyclic phosphorothioates by cyclothiophosphorylation of unprotected nucleosides. Tetrahedron Lett 29: 2803–2804.
64. Klayman DL, Griffin TS, (1973) Reaction of selenium with sodium-borohydride in protic solvents—facile method for introduction of selenium into organic-molecules. J Am Chem Soc 95: 197–200.
65. Chu SH, Shiue CY, Chu MY, (1974) Synthesis and biological-activity of some 8-substituted seleno cyclic nucleotides and related compounds. J Med Chem 17: 406–409. 4364508
66. Long RA, Robins RK, Townsend LB, (1967) Purine nucleosides.15. synthesis of 8-amino- and 8-substituted aminopurine nucleosides. J Org Chem 32: 2751–&. 6073218